Filing Details
- Accession Number:
- 0001415889-24-019526
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-12 16:55:07
- Reporting Period:
- 2024-07-10
- Accepted Time:
- 2024-07-12 16:55:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1907108 | Lexeo Therapeutics Inc. | LXEO | Biological Products, (No Disgnostic Substances) (2836) | 854012572 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1995218 | Nolan Richard Townsend | C/O Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York NY 10010 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-07-10 | 5,000 | $2.33 | 175,695 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-10 | 23,622 | $16.45 | 152,073 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-10 | 3,347 | $16.85 | 148,726 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-11 | 27,931 | $17.06 | 120,795 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-11 | 100 | $19.06 | 120,695 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-07-10 | 5,000 | $0.00 | 5,000 | $2.33 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 138,655 | 2031-02-15 | No | 4 | M | Direct |
Footnotes
- The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
- This transaction was executed in multiple trades at prices ranging from $15.83 to $16.825. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $16.83 to $16.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $16.7476 to $17.4703. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Billionaire Hedge Funds
